Search

Displaying results 4731 - 4740 of 5040 in total
  1. Drug

    Lepzacitinib

    go.drugbank.com/drugs/DB21646
    Investigational

    Lepzacitinib has a monoisotopic molecular weight of 355.16 Da.

  2. Drug

    Luvometinib

    go.drugbank.com/drugs/DB21696
    Investigational

    Luvometinib has a monoisotopic molecular weight of 665.04 Da.

  3. Drug

    Inlexisertib

    go.drugbank.com/drugs/DB21713
    Investigational

    Inlexisertib has a monoisotopic molecular weight of 535.29 Da.

  4. Drug

    Pebezertinib

    go.drugbank.com/drugs/DB21705
    Investigational

    Pebezertinib has a monoisotopic molecular weight of 497.16 Da.

  5. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies.

  6. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675]

  7. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]

  8. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated

  9. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  10. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].